We operate worldwide, with headquarters in Israel and a significant presence in the United States, Europe and many other markets around the world. Today, our global network of capabilities consists of approximately 34,000 employees across 57 markets. Teva was incorporated in Israel on February 13, 1944 and is the successor to a number of Israeli corporations, the oldest of which was established in 1901.
Cash figures as of 2026-09-30. Database snapshot: 2026-11-07.
Share structure
Common
1,165.3M
Pre-funded warrants
0.0M
Options
—
RSUs
—
Warrants
0.0M
Converts
—
Conv preferred
0.0M
ESPP reserve
0.0M
FDSO
1,165.3M
Cap table as of 2026-06-30.
Price history
Loading TEVA daily closes…
Loading price history…
Next catalyst
TEV-'749 · Est. Nov 15, 2026 · quarter midpoint · guided Now
Recently reported
TEV-56286 Phase 2Negative · 2026-11-02
TOPAS-MSA · multiple system atrophy
Primary: Change from baseline to Week 48 in the modified Unified Multiple System Atrophy Rating Scale Part I score (Phase 2 TOPAS-MSA, NCT06568237) — Prespecified interim futility analysis met the predefined futility criterion, indicating a low probability of the study meeting its primary efficacy endpoint if continued; Teva will discontinue the study on the independent data monitoring committee's recommendation. No numeric efficacy result was disclosed; the analysis was an interim predictive assessment, not the final efficacy analysis
· Study designed to enroll approximately 350 participants to receive emrusolmin 300 mg or placebo for approximately 48 weeks, followed by a four-week follow-up
· Open-label extension study NCT07197866; a comprehensive analysis of TOPAS-MSA and available OLE data will follow
· The decision concerns TOPAS-MSA and does not represent a final decision on the broader emrusolmin program
Safety: No safety concerns were identified in the interim analysis
Primary: Clinical remission (modified Mayo Score) in ulcerative colitis and endoscopic response (50% or greater decrease in SES-CD) in Crohn's disease at Week 44 of maintenance treatment — UC clinical remission 47% on duvakitug 450 mg (n=34) and 58% on 900 mg (n=38); CD endoscopic response 41% on 450 mg (n=27) and 55% on 900 mg (n=31)
· RELIEVE UCCD LTE (NCT05668013): n=130 induction responders (72 UC, 58 CD) re-randomized to duvakitug 450 mg or 900 mg SC every four weeks
· Efficacy numerically higher at 900 mg in both diseases, consistent with a dose response
Safety: Generally well tolerated, safety consistent with the induction phase, no new safety concerns; discontinuations due to adverse events were UC 4% (450 mg) and 2% (900 mg), and CD 6% in each arm
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Partnerships MedinCell: development and commercialization of long-acting injectable products; Teva leads clinical development and regulatory process
Indications
Schizophrenia(Phase 3)
Status note Phase 3 completed. NDA submitted December 2025 (accepted February 2026); EMA MAA accepted May 2026.
ecopipam
Phase 3 · ActiveModality: small molecule
Aliases EBS-101
Target dopamine D1 receptor
Partnerships Emalex Biosciences: Teva acquired all outstanding shares June 2026 (~$700M); former shareholders eligible for milestones up to $200M plus royalties
Indications
Tourette syndrome (pediatric)(Phase 3)
Status note Phase 3 completed. NDA submitted to FDA June 18, 2026.
duvakitug
Phase 3 · ActiveModality: monoclonal antibody
Aliases TEV-574
Target TL1A
Partnerships Sanofi: collaboration (upfront $500M; $250M milestones per indication achieved Q4 2025); Sanofi leads Phase 3 development; 50/50 development cost and profit/loss share in major markets. Blackstone Life Sciences: up to $400M development funding
Indications
Ulcerative colitis(Phase 3)
Crohn's disease(Phase 3)
Hidradenitis suppurativa(Stage not disclosed)
Fibrostenotic Crohn's disease(Stage not disclosed)
Catalysts
— 2026
— 2026
Status note Phase 3 studies for ulcerative colitis and Crohn's disease initiated October 2025 by Sanofi and Teva.
emrusolmin
Phase 2 · Active
Aliases TEV-286
Partnerships Modag GmbH: exclusive global license to develop, manufacture and commercialize
Indications
Multiple System Atrophy (MSA)(Phase 2)
Parkinson's disease(Stage not disclosed)
Status note Phase 2 clinical trial for MSA initiated Q3 2024. FDA Fast Track designation for MSA (September 2025).
TEV-287
Phase 1 · Active
Partnerships Modag GmbH: collaboration
Indications
Parkinson's disease(Phase 1)
Status note Phase 1 clinical trial initiated Q2 2025.
TEV-408
Phase 1 · ActiveModality: monoclonal antibody
Target IL-15
Partnerships Royalty Pharma: funding agreement (up to $75M R&D funding; option for additional $425M based on Phase 2b results)
Indications
Vitiligo(Phase 1)
Celiac disease(Stage not disclosed)
Catalysts
— Q4 2026
Status note Phase 1b results completed; advancing to Phase 2b in vitiligo.
Partnerships Launch Therapeutics: clinical collaboration to accelerate the clinical research program. Abingworth: development funding
Indications
Asthma(Phase 3)
Status note Phase 3 trial ongoing; targeted initial enrollment levels in adult and pediatric populations achieved by end 2025.
BD9
Stage not disclosed · ActiveModality: multibody
Aliases TEV-325
Partnerships Biolojic Design: Teva received exclusive rights to develop, manufacture and globally commercialize
Indications
Asthma(Stage not disclosed)
Atopic dermatitis(Stage not disclosed)
Status note Early-stage multibody with potential indications including asthma and atopic dermatitis.
Per-asset detail extracted from the 10-Q filed 2026-07-29. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (9 as sponsor, 12 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.